文献速递肝胆胰外科围术期管理与 ERAS

胰腺导管腺癌术后孤立性复发的外科治疗管理

Management of isolated recurrence after surgery for pancreatic adenocarcinoma.
PubMed 文献 · Br J Surg · 2019-01-01

结论认为手术切除可考虑作为孤立性复发的治疗选择。

核心结论

  • 手术切除可考虑作为胰腺癌孤立性复发的治疗选择。
  • 化疗和复发后切除均与更好的预后相关。

研究设计与样本

  • 单中心大容量中心2000至2014年根治性胰腺切除患者的回顾性研究。
  • 采用CT或PET筛选孤立性复发患者,按治疗方式比较临床病理特征和生存结局。

主要发现

  • 多因素分析显示化疗和复发后切除与更好预后相关。

临床怎么用

  • 对胰腺癌术后孤立性复发患者,尤其是残胰和肺孤立性复发,可考虑手术切除。
  • 复发后化疗与更好预后相关,应结合全身治疗综合决策。

局限性

  • 单中心回顾性研究,存在选择偏倚可能。
  • 孤立性复发接受切除的样本量较小(48例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence of pancreatic cancer after primary pancreatectomy occurs in the vast majority of patients. The role of surgical treatment for recurrent pancreatic cancer is not well established. METHODS: Patients who underwent primary pancreatectomy with curative intent from 2000 to 2014 at a single large-volume centre were evaluated retrospectively. CT or PET was used to select patients with an isolated recurrence. The clinicopathological features and survival outcomes were compared according to treatment modalities. RESULTS: Of the 1610 patients with pancreatic cancer who underwent resection, 1346 (83·6 per cent) were diagnosed with recurrent pancreatic cancer. Recurrence was locoregional in 366 patients (27·2 per cent), distant multifocal in 251 (18·6 per cent), distant isolated in 188 (14·0 per cent), locoregional plus distant in 153 (11·4 per cent) and peritoneal seeding in 388 (28·8 per cent). Of the 1346 patients with recurrence, 197 (14·6 per cent) had isolated recurrence; of these, 48 (24·4 per cent of all isolated recurrences; 3·6 per cent of all recurrences) underwent resection. Median survival of the 197 patients after diagnosis of isolated recurrence was 14·7 months; it was longer in patients who underwent surgical resection than among those treated non-surgically (23·5 versus 12·0 months; P = 0·014). Multivariable analysis showed that chemotherapy and resection for recurrence were associated with better prognosis. Median survival after recurrence was longest in the 23 patients with isolated pulmonary recurrence (33·3 months). Survival after recurrence was better in patients who underwent resection of isolated recurrence in the remnant pancreas (median 28·0 versus 12·0 months, P = 0·010) and lung (median 36·5 versus 9·5 months; P = 0·010) than in those who did not undergo resection. CONCLUSION: Surgical resection may be considered an option for treatment of patients with isolated recurrent pancreatic cancer.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Kim YI, Song KB, Lee YJ, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019. PMID: 31162655. doi:10.1002/bjs.11144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。